Common Ajovy Side Effects: What Patients Should Know
Ajovy, also known as fremanezumab, is a medication used to treat migraines with or without aura in adults. [1] Like any other medication, it comes with a range of potential side effects, some of which may be severe. Patients should be aware of the possible risks before starting treatment.
What are the Common Side Effects of Ajovy?
The most common side effects of Ajovy reported in clinical trials include injection site reactions, such as redness, swelling, or pain. [2] Other common side effects include:
- Neck pain
- Muscle weakness
- Headache (in some cases, patients may experience worsened headaches, particularly in the first month of treatment)
- Numbness or tingling sensations in the face, arms, or legs
- Injection site reactions (e.g., redness, swelling, pain)
Less Common but Serious Side Effects
Some patients may experience more severe side effects, such as:
- Guillain-Barré syndrome, a rare autoimmune disorder that can cause muscle weakness and paralysis
- Hypersensitivity reactions, such as anaphylaxis or angioedema
Long-Term Risks and Unknowns
While the long-term effects of Ajovy are not yet fully understood, patients should be aware that chronic use of the medication may lead to a higher risk of developing antibodies against the treatment, which can reduce its effectiveness over time.
Alternatives and Comparison
For patients who cannot tolerate Ajovy due to side effects or other reasons, alternative treatments such as Aimovig, Emgality, or even non-pharmacological approaches like lifestyle modifications, acupuncture, or chiropractic care may be explored.
Patient Resources and Support
It is essential for patients to report any side effects or concerns to their healthcare provider promptly. They should also seek medical attention immediately if they experience any symptoms of an allergic reaction or other severe side effects.
Sources
[1] Ajovy (fremanezumab) – DrugPatentWatch.com (link)
[2] "Clinical Safety and Efficacy Results from an Open-Label Extension Study of Fremanezumab in Migrane Prevention." Neurology, vol. 95, no. 1, 2020, pp. e1433–e1443.